FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum  Kyntra Bio (Nasdaq: KYNB) is the new name for FibroGen, effective at market open on January 8, 2026, reflecting a strategic refocus on oncology and rare disease.Key corporate moves in 2025 included the sale of FibroGen China, payoff of a senior secured term loan, and an announced extension of the company cash runway into 2028. Lead clinical programs are FG-3246 (CD46-targeting ADC) and companion PET agent FG-3180 in prostate cancer, with topline ASCO GU data expected in Q1 2026 and Phase 2 interim results in H2 2026. Roxadustat received Orphan Drug Designation for MDS and a Phase 3 protocol for anemia in lower-risk MDS was submitted to the FDA.

#FGEN FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum 

www.stocktitan.net/news/FGEN/fibro-gen-rebr...

ITちゃんねる U22プロコン2025開催、経済産業大臣賞に中学生の伊藤碧さん #Fgen #ITニュース

U22プロコン2025開催、経済産業大臣賞に中学生の伊藤碧さん
#Fgen #ITニュース

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration FibroGen (NASDAQ: FGEN) announced that the U.S. FDA granted Orphan Drug Designation to roxadustat for the treatment of myelodysplastic syndromes (MDS) on Dec 15, 2025. The designation may provide fee exemptions, clinical development incentives, and 7 years of U.S. market exclusivity if approved. A post-hoc analysis from the Phase 3 MATTERHORN trial reported roxadustat benefit for transfusion independence in a subset of patients with high transfusion burden. FibroGen is finalizing a Phase 3 protocol for this MDS population and plans to submit it to the FDA in Q4 2025. The company noted ~58,000 LR-MDS patients in the U.S., with ~85% experiencing anemia and many facing transfusion dependence and related complications.

#FGEN Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

www.stocktitan.net/news/FGEN/roxadustat-gra...

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update Completed the sale of FibroGen China to AstraZeneca for approximately $220 million Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC) Reached agreement with the U.S.

#FGEN FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/FGEN/fibro-gen-repo...

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer FibroGen (NASDAQ: FGEN) has launched a Phase 2 monotherapy trial for FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in metastatic castration-resistant prostate cancer (mCRPC) patients.The trial will enroll 75 patients randomized into three dosing groups (1.8, 2.4, or 2.7 mg/kg AJBW) and includes patients who have progressed after ARSI treatment but haven't received chemotherapy. The study will also evaluate FG-3180, a companion PET imaging agent, as a potential diagnostic and predictive biomarker.An interim analysis is expected in 2H 2026, while topline results from a separate investigator-sponsored study of FG-3246 combined with enzalutamide are anticipated in Q4 2025. The company reports having cash runway extending into 2028.

#FGEN FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

www.stocktitan.net/news/FGEN/fibro-gen-init...

Trade Alerts, Monday September 8, 2025 – Crystal Equity Research

Small-cap stocks with bearish MACD Xs, Mon Sept 8th - #VIRC #OKUR #NBN #MOGO #JBSS #HIVE #GASS #FGEN #EQ #SNT #DYN #CCNE #ALXO #YEXT #WTI #SD #PDS #PACK #PDSB #NXDR #INVX #HE #GRNT #EGY #CYD #BFS #ALEX - More: crystalequityresearch.com/trade-alerts... - #smallcap

$220M Deal: FibroGen Divests China Operations to AstraZeneca, Extends Cash Runway to 2028 Biotech firm sells China subsidiary for $220M ($85M enterprise value, $135M net cash). Deal repays Morgan Stanley loan, extends runway to 2028. Phase 2 trial for prostate cancer drug on track for Q3.

#FGEN FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

www.stocktitan.net/news/FGEN/fibro-gen-comp...

Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators China's market regulator approves FibroGen's sale of its China operations to AstraZeneca Treasury Limited. Deal expected to close in Q3 2025, pending final conditions.

#FGEN FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

www.stocktitan.net/news/FGEN/fibro-gen-anno...

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update FibroGen (NASDAQ: FGEN) reported its Q2 2025 financial results and significant business updates. The company announced an increased total consideration of $210 million for the sale of FibroGen China to AstraZeneca, representing a $50 million increase from initial guidance. The transaction, expected to close in Q3 2025, includes an enterprise value of $85 million plus approximately $125 million in net cash.Key financial results show Q2 2025 revenue of $1.3 million and a net loss of $13.7 million. The company reported $142.1 million in total consolidated cash and expects its cash runway to extend into 2028 post-China sale.In clinical developments, FibroGen reached an agreement with the FDA on Phase 3 trial design for roxadustat in LR-MDS patients and plans to initiate a Phase 2 trial of FG-3246, their CD46-targeting ADC, in metastatic castration-resistant prostate cancer in Q3 2025. [ "Sale of FibroGen China increased by $50 million to $210 million total consideration", "Cash runway expected to extend into 2028 after China sale closes", "FDA agreement reached on Phase 3 trial design for roxadustat in LR-MDS", "Net loss decreased significantly from $47.1M in Q2 2024 to $13.7M in Q2 2025", "Revenue increased 30% year-over-year to $1.3M in Q2 2025" ]

#FGEN FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/FGEN/fibro-gen-repo...

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes FibroGen (NASDAQ: FGEN) has received positive feedback from the FDA during a Type C meeting regarding roxadustat for treating anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell transfusion burden.The feedback was based on promising post-hoc analysis data from the MATTERHORN Phase 3 trial, where roxadustat showed significant efficacy: 36% (8/22) of patients achieved transfusion independence versus 7% (1/15) in the placebo group. The company plans to initiate a new Phase 3 trial with approximately 200 patients, with the protocol submission expected in Q4 2025.The planned study will be randomized, double-blind, and placebo-controlled, targeting patients requiring ≥4 pRBC units in consecutive 8-week periods who are refractory to, intolerant to, or ineligible for prior ESA therapy.

#FGEN FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

www.stocktitan.net/news/FGEN/fibro-gen-anno...

Transgender campaigners call for European rights body to report on UK Alliance of groups wants Council of Europe to investigate implementation of supreme court ruling on biological sex

Huge thanks to @cobieef.bsky.social, @jessothomson.co.uk, @helenbelcherobe.bsky.social @transsolidarity.bsky.social @transactualuk.bsky.social #FGEN @transsafety.network #EqualityNetwork @scottishtrans.bsky.social

Coverage from @theguardian.com here:

www.theguardian.com/society/2025...

Inspired by @katymontgomerie.com 's talk at #FGEN conference about arguing with anti trans people online, and how it's not about them but about people who might be watching the conversation, i have replied to something i wouldn't normally reply to. Let's see how that works out for me shall we.

Amazing day at the #FGEN Trans Liberation Now conference.

First time ever presenting on my MA that I finished 6 years ago 😂 got some lovely encouragement to think about extending the themes to a PHD which was a nice confidence boost.

Also lovely to meet @mimmymum.bsky.social 💖

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Tue Jun 17th - #YQ #SEDG #RUN #IMRX #FGEN #BNTC #ALDF #VNCE #RDW #LTM #FVR #CTRI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

FibroGen Announces 1-for-25 Reverse Stock Split FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen’s common stock

#FGEN FibroGen Announces 1-for-25 Reverse Stock Split

www.stocktitan.net/news/FGEN/fibro-gen-anno...

My paper, based on my MA dissertation and submitted on a whim, has been accepted for presentation at the #FGEN conference in June.

I'm going to bin the imposter syndrome and go for it.

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update FibroGen (NASDAQ: FGEN) reported its Q1 2025 financial results and business updates. The company announced an increased total consideration of $185 million for the sale of FibroGen China to AstraZeneca, up $25 million from initial guidance, with approximately $100 million in net cash held in China at closing. The transaction is expected to close in Q3 2025, extending the company's cash runway into 2H 2027. Key developments include the planned initiation of a Phase 2 monotherapy trial for FG-3246, their lead ADC targeting CD46 in metastatic castration-resistant prostate cancer, in Q3 2025. The company reported Q1 2025 revenue of $2.7 million, down from $25.4 million in Q1 2024, and a net loss of $16.8 million ($0.16 per share). FibroGen also filed a Type-C meeting request with the FDA regarding roxadustat for anemia associated with lower-risk myelodysplastic syndromes.

#FGEN FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/FGEN/fibro-gen-repo...

Email sent to over 80 MPs and Ministers - Feminist Gender Equality Network Yesterday we sent the following email to over 80 MPs and ministers across multiple parties and geographical boundaries. As you will be aware, last Wednesday’s UK Supreme Court ruling overturned how th...

Feeling fired-up as part of this democratic and activist effort responding to the recent UK Supreme Court exclusionary ruling about "sex".

feministgenderequality.network/email-sent-t...

#FGEN #transwomenarewomen #transrightsarehumanrights

🚨UPDATE!
-The letter gathered 4,254 signatures😲
-@transactualuk.bsky.social & #FGEN are supporting
-Letter will now go to ~80 MPs across all parties & depts
- Missed the deadline but still want to support trans rights? Options here: docs.google.com/forms/d/e/1F...
-more helpful resources coming soon

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results FibroGen (NASDAQ: FGEN) has announced the sale of FibroGen China to AstraZeneca for approximately $160 million, comprising an $85 million enterprise value plus estimated $75 million net cash at closing. The transaction, expected to close by mid-2025, will extend the company's cash runway into 2027.Key financial results for 2024 show total revenue from continuing operations at $29.6 million, down from $46.8 million in 2023. The company reported a net loss of $153.1 million ($1.53 per share) for 2024, improved from a $323.0 million loss ($3.32 per share) in 2023.Notable upcoming milestones include: Initiation of Phase 2 monotherapy trial for FG-3246 in metastatic castration-resistant prostate cancer by mid-2025Expected topline results from Phase 2 combination study with enzalutamide in 2H 2025Planned FDA meeting in Q2 2025 regarding roxadustat development for anemia in lower-risk myelodysplastic syndrome

#FGEN FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/FGEN/fibro-gen-repo...

Ex divis this week
#ASLI
#TRI
#DOCS
#CFX
#GLE
#PZC
#TMPL
#NEXS
#S32
#RSW
#FGEN
#WIL
#BHP
#AGR
#HSBA
#RIO
#RIII
#JGGI
#ENRG
#UEM
#CLIG
#PNL
#RCOI
#JEMI
#PMGR
#LMP
#HICL
#VSL
#NAS
#BBGI
#ENOG
#GNS
#MWY
#BKG
#RMII

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Thu Feb 20th - #ANIX #VS #SABR #AMPL #CADL #FGEN #INSG #LUNG #NEGG #OESX #CYD #ENFN #HLF #MD #XYF #RCB #TIF #PRPH #TCRX #XOS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

BREAKING NEWS: ( NASDAQ: #FGEN ) This Small Cap Soared Following Subsidiary Sale Announcement Worth $160M

Inside FibroGen's $160M China Exit: Strategic Pivot or Cash Grab? Strategic sale strengthens balance sheet with $160M infusion, enables debt repayment, and funds oncology pipeline advancement while extending operations through 2027.

#FGEN FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

www.stocktitan.net/news/FGEN/fibro-gen-anno...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FGEN 79% OTM
2. #RILY 70% OTM
3. #SANA 58% OTM
4. #ABR 50% OTM
5. #RAPT 49% OTM

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FGEN 135% OTM
2. #GME 103% OTM
3. #CVNA 57% OTM
4. #NNOX 48% OTM
5. #MARA 42% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FGEN, #CVNA, #NNOX, #PRU, #BILI

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FGEN 135% OTM
2. #GME 122% OTM
3. #CVNA 69% OTM
4. #NNOX 48% OTM
5. #NKLA 34% OTM

#OptionFlow #OptionsTrading #Trading